Results 71 to 80 of about 169,844 (308)
Risk and Reward: Extending stochastic glycaemic control intervals to reduce workload [PDF]
, 2020 peer reviewedBackground STAR is a model-based, personalised, risk-based dosing approach for glycaemic control (GC) in critically ill patients. STAR provides safe, effective control to nearly all patients, using 1-3 hourly measurement and intervention ...
Uyttendaele, Vincent +4 more
core +1 more source
Cracking the Code: Genotype–Phenotype Correlation Models in Sarcoglycanopathies
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Sarcoglycanopathies are among the most severe limb‐girdle muscular dystrophies (LGMD), though milder presentations have been described. These diseases are primarily caused by missense variants, but the limited predictability of their effect on protein maturation, complex formation, and transport has hindered reliable genotype ...
Leonela Luce +72 more
wiley +1 more source
SPG4 and Dementia: Expanding the Clinical Spectrum
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Hereditary spastic paraplegia (HSP) is a group of disorders characterized by progressive spasticity and lower limb weakness, with mutations in SPG4/SPAST being the most common cause. Detailed studies and clinical and molecular comparisons across different populations are missing.
Emanuele Panza +19 more
wiley +1 more source
, 2022 Cancer with all its more than 200 variants continues to be a major health problem around the world with nearly 10 million deaths recorded in 2020, and leukemia accounted for more than 300,000 cases according to the Global Cancer Observatory. Although new
Raul Garrido +9 more
core +1 more source
RNA Sequencing Resolves Cryptic Pathogenic Variants in Mitochondrial Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Mitochondrial diseases are the most common inherited metabolic disorders, characterized by pronounced clinical and genetic heterogeneity that complicates molecular diagnosis. Although DNA‐based sequencing approaches have become standard in genetic testing, up to half of patients remain without a definitive diagnosis.
Zhimei Liu +21 more
wiley +1 more source
In silico and in vitro approaches to develop Dimethylarginine dimethylaminohydrolase-1 inhibitors [PDF]
, 2017 Introduction: Dimethylarginine dimethylaminohydrolases (DDAH) metabolise the endogenous nitric oxide synthase (NOS) inhibitors: asymmetric dimethylarginine (ADMA) and monomethylarginine1.
Smith, C.L., Zloh, M., Rossiter, S.
core
Design principle of heparanase inhibitors: a combined in vitro and in silico study
, 2023 Heparanase (HPSE) is an enzyme responsible for the cleavage of heparan sulfate (HS) side chains from heparan sulfate proteoglycans (HSPGs). The enzymatic activity of HPSE contributes to ECM remodeling, regulates growth factors, and its overexpression has
Jun, Liu +6 more
core +1 more source
Application of Ibuprofen Sodium Dihydrate for Thermochemical Energy Storage
Advanced Functional Materials, EarlyView.Ibuprofen sodium dihydrate is introduced as a durable organic salt hydrate for low‐temperature thermochemical energy storage, operating within 60°C–110°C with high energy density. At the material level, it delivers ∼99.9% cycling efficiency over 150 cycles without deliquescence, enabled by a dual energy‐storage mechanism coupling dehydration and phase ...
Kavin Chakravarthy Thangaraj +10 more
wiley +1 more source
Results in ChemistryCell function depends on redox homeostasis, and several diseases are linked to its disruption. The relative amounts of reduced and oxidised glutathione play a major role in controlling redox balance.
Mohammed Salah Ayoup +8 more
doaj +1 more source
Automated in Silico Design of Homogeneous Catalysts [PDF]
, 2020 Catalyst discovery is increasingly relying on computational chemistry, and many of the computational tools are currently being automated. The state of this automation and the degree to which it may contribute to speeding up development of catalysts are ...
Jensen, Vidar Remi +3 more
core +1 more source